358 related articles for article (PubMed ID: 33841966)
41. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinoma.
Yan S; Liu L; Zhang X; Wei L; Jiang W; Gao X; Yang A; Liu X; Chen W; Chen Y; Li H; Lin Q; Li M; Chen J; Zhang Q; Chen S; Song M
Clin Transl Oncol; 2024 May; 26(5):1192-1202. PubMed ID: 37989823
[TBL] [Abstract][Full Text] [Related]
43. Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer.
Chen Y; Yan B; Xu F; Hui Z; Zhao G; Liu J; Zhang H; Zeng Z; Zhang R; Provencio M; Ren X; You J
Transl Lung Cancer Res; 2021 May; 10(5):2193-2204. PubMed ID: 34164269
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.
Wang K; Gui L; Lu H; He X; Li D; Liu C; Liu S; Wang X
Front Immunol; 2023; 14():1189752. PubMed ID: 37583698
[TBL] [Abstract][Full Text] [Related]
45. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study.
Lin W; Huang Y; Zhu L; Li W; Zhao L; Pan X; Lin J; Guo T
J Gastrointest Oncol; 2022 Dec; 13(6):2758-2768. PubMed ID: 36636044
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
48. [Non-small cell lung cancer (NSCLC) stage IIIA/IIIB. A pilot study of neoadjuvant chemotherapy with paclitaxel and carboplatin].
Ukena D; Leutz M; Schlimmer P; Huwer H; Schäfers HJ; Sybrecht G
Med Klin (Munich); 1997 Dec; 92 Suppl 5():49-53. PubMed ID: 19479398
[TBL] [Abstract][Full Text] [Related]
49. Single-port video-assisted thoracoscopic sleeve lobectomy after neoadjuvant immunochemotherapy: a case report.
Chen H; Zhang J; Rossi A; Divisi D; Chen C; Zheng B
Transl Lung Cancer Res; 2024 Feb; 13(2):423-433. PubMed ID: 38496704
[TBL] [Abstract][Full Text] [Related]
50. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
He W; Leng X; Mao T; Luo X; Zhou L; Yan J; Peng L; Fang Q; Liu G; Wei X; Wang K; Wang C; Zhang S; Zhang X; Shen X; Huang D; Yi H; Bei T; She X; Xiao W; Han Y
Oncologist; 2022 Feb; 27(1):e18-e28. PubMed ID: 35305102
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
Yao Y; Tang D; Gao W; Zhang H
Front Surg; 2022; 9():843987. PubMed ID: 35449550
[TBL] [Abstract][Full Text] [Related]
52. Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer.
Zhang L; Mai W; Jiang W; Geng Q
Front Surg; 2020; 7():601805. PubMed ID: 33330611
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.
Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J
Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
[TBL] [Abstract][Full Text] [Related]
55. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
57. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
59. Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study.
Zhang W; Li Y; Xue L; Qu D; Jiang Z; Wang Z; Yang Z; Zhou A
Cancer Manag Res; 2021; 13():2163-2170. PubMed ID: 33688259
[TBL] [Abstract][Full Text] [Related]
60. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
